MedTrace Logo

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

NCT00449930 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1050

Last updated 2017-05-11

Study results available
· View outcomes & findings →

Summary

A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes

Conditions

Interventions

DRUG

sitagliptin phosphate

(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period

DRUG

Comparator: metformin hydrochloride

(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-01
Primary Completion
2008-07-25
Completion
2008-07-25

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449930 on ClinicalTrials.gov